We are moving!

20 December

2021

We are moving!

On December 18, 2021, Pure Biologics signed a contract for the lease of space for a new headquarters.

Dr. Pieter Spee is the new Chief Scientific Officer

1 June

2021

Dr. Pieter Spee is the new Chief Scientific Officer

Dr. Pieter Spee, a medical biologist and manager with many years of experience in international biopharmaceutical companies, was appointed to the position of Chief Scientific Officer, CSO.

Recommendations for the Pure Biologics company shares

26 May

2021

Recommendations for the Pure Biologics company shares

Dom Maklerski BOŚ recommends the purchase of Pure Biologics shares.

Pure Biologics teams up with Twist Bioscience

15 April

2021

Pure Biologics teams up with Twist Bioscience

Pure Biologics joins efforts with Twist Bioscience to expand the capabilities of the phage display technology used in Pure Biologics' portfolio of immuno-oncology projects.

Project PB002 – preclinical research partner selected

19 March

2021

Project PB002 – preclinical research partner selected

Pure Biologics has selected a partner to lead the first panel of preclinical studies in the PB002 aptamer project

W poszukiwaniu nowych leków i przełomowych terapii – article in “Rzeczpospolita”

3 March

2021

W poszukiwaniu nowych leków i przełomowych terapii – article in “Rzeczpospolita”

An article presenting global trends in pharmaceutical R&D and how Polish companies fit into them.

1
2
3
4
5
6

9 October

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

17 June

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

10 April

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020

25 January

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/2/20 25.01.2020

21 January

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/1/20 21.01.2020

1
2

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.